Astrazeneca Pharma India Ltd vs Natco Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8217 as of 30 Apr 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Natco Pharma Ltd changed from 34.2 on March 2021 to 7.6 on March 2025 . This represents a CAGR of -25.98% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 15045 crore on March 2021 to ₹ 14287 crore on March 2025 . This represents a CAGR of -1.03% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Natco Pharma Ltd for the Dec '25 is ₹ 705.4 crore as compare to the Sep '25 revenue of ₹ 1463 crore. This represent the decline of -51.78% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Natco Pharma Ltd for the Dec '25 is ₹ 216.8 crore as compare to the Sep '25 ebitda of ₹ 679.2 crore. This represent the decline of -68.08% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Natco Pharma Ltd changed from ₹ 668.5 crore to ₹ 140.4 crore over 7 quarters. This represents a CAGR of -59.01% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Natco Pharma Ltd changed from 30.96 % on March 2021 to 5.8 % on March 2025 . This represents a CAGR of -28.46% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Natco Pharma Ltd

Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company as 'Natco Fine Pharmaceuticals Private Limited'.
The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation dated 30 December 1994 issued by the RoC, Andhra Pradesh. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
The Company's focus is primarily on niche therapeutic areas and complex products.
It sells products in over 40 countries.
FDF products are sold in the United States, India, Europe and the rest of the world (RoW).

FAQs for the comparison of Astrazeneca Pharma India Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Natco Pharma Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,543 Cr while Market cap of Natco Pharma Ltd is 19,627 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Natco Pharma Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Natco Pharma Ltd?

As of May 3, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8217.2. On the other hand, Natco Pharma Ltd stock price is INR ₹1095.85.

How do dividend payouts of Astrazeneca Pharma India Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.